| Title: |
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study |
| Authors: |
Cohen, Deirdre J; Goldberg, Judith D; Leichman, Lawrence; Hochman, Tsivia; Newman, Elliot; Du, Kevin; Megibow, Alec; Oberstein, Paul; Al-Rajabi, Raed; Scott, Aaron J; Bekaii-Saab, Tanios; Messersmith, Wells A; Weekes, Colin |
| Contributors: |
NCI Cancer Center; NYU Grossman School of Medicine |
| Source: |
The Oncologist ; volume 30, issue 10 ; ISSN 1083-7159 1549-490X |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2025 |
| Description: |
Background Surgical resection without visible or residual microscopic disease (R0 resection) is known as the optimal path to cure localized pancreatic cancer (PDAC). Neoadjuvant therapy (NAT) is used to improve R0 resection rates; however, the optimal regimen is unclear. We assessed the safety and efficacy of peri-operative gemcitabine/nab-paclitaxel (GEM/NAB) and pre-operative stereotactic body radiotherapy (SBRT) in patients with resectable (R-PDAC) and borderline resectable PDAC (BR-PDAC). Patients and Methods This was a prospective, multicenter single arm phase 2 study in patients with R-PDAC and BR-PDAC. Patients received three cycles of GEM/NAB prior to SBRT followed by surgery and three cycles of adjuvant GEM/NAB. Primary endpoint was R0 surgical resection rate in each cohort. Secondary endpoints included safety and overall survival (OS). Results Eighty-six patients consented and following radiologic screening, 49 were enrolled into two cohorts: R-PDAC (n = 20) and BR-PDAC (n = 29) between June 2016 and April 2021. Seventy percent of R-PDAC (14/20) and 55.2% of BR-PDAC patients (16/29) completed all NAT. Eleven R-PDAC (55.0%) and 11 BR-PDAC patients (37.9%) underwent surgical resection. Nine R-PDAC (45.0%) and 9 BR-PDAC patients (31.0%) had R0 resections. The median OS for R-PDAC and BR-PDAC patients with R0 resections was 22 months (95% CI: 17.7 months-NA) and 39 months (95%CI: 13.21 months-NA), respectively. Conclusion While the trial failed to meet one of its primary objectives as only 45% of R-PDAC patients had an R0 resection, the objective of 30% R0 resection for the BR-PDAC group was met. NAT should be part of current therapeutic strategies for BR-PDAC; however, our trial does not answer what is the best NAT for BR-PDAC. Trial Registration NCT02723331 |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/oncolo/oyaf271 |
| DOI: |
10.1093/oncolo/oyaf271/64287749/oyaf271.pdf |
| Availability: |
https://doi.org/10.1093/oncolo/oyaf271; https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyaf271/64287749/oyaf271.pdf; https://academic.oup.com/oncolo/article-pdf/30/10/oyaf271/64287749/oyaf271.pdf |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.931092A1 |
| Database: |
BASE |